Stop FDA’s ‘Sudden’ Biosecurity Overreach: Newsletter
The staff of the online newsletter Global Biodefense raises a concern that FDA’s recent action stopping clinical trials that involve shipping participants’ biological samples to laboratories in China and other “hostile” countries can cripple biomedical innovation and progress in the U.S. “The stated concern is that overseas sample processing and data analysis might expose Americans’ sensitive genetic data to foreign misuse,” the newsletter says. “But beneath the national security narrative lies a broader, more troubling pattern.”
Global Biodefense says the agency action reverses a legal and regulated exemption granted under a 12/2024 data security rule finalized by the Biden administration after months of public comment and stakeholder engagement. It says the rule created a framework for managing the export of sensitive personal data to countries of concern while still allowing clinical research to proceed. It included a narrow exemption for FDA-regulated trials, it says, provided they adhered to ethical consent standards and oversight.
According to the post, that exemption reflected the essential operational reality that U.S.-based biotech companies routinely rely on lower-cost, high-throughput international laboratories to process and analyze clinical trial samples. The infrastructure to perform all such work domestically simply doesn’t exist at the necessary scale, it says.
“Yet, with no formal rulemaking or quantified risk assessment, FDA has now imposed a blanket freeze,” the article says. “The agency cited ‘mounting evidence’ that some trials may have failed to disclose the international handling of samples, but did not identify specific violations, security breaches, or affected participants.”
The post says that FDA commissioner Martin Makary said the Biden administration “turned a blind eye,” even though the exemption at issue was published, scrutinized, and implemented through a transparent, participatory process published in the Federal Register.
“This sudden shift could have wide-ranging effects on the pace and feasibility of U.S. clinical research,” the post says. “Innovative therapies, especially in oncology, regenerative medicine, and rare diseases, often depend on rapid turnaround for sample analysis and biomarker validation. Without access to global lab capacity, sponsors may face steep delays or be forced to redesign studies around suboptimal domestic options.”
The post concludes that the policy shift not only affects researchers and companies but could also jeopardize public health. “If the U.S. becomes a difficult or unpredictable environment for conducting trials,” it says, “research will migrate elsewhere. Over time, that weakens the domestic pipeline of innovation, slows regulatory readiness, and diminishes global leadership in biomedicine.”